Iovance Biotherapeutics Inc (NASDAQ:IOVA) has a beta value of 0.86 and has seen 9.05 million shares traded in the last trading session. The company, currently valued at $617.78M, closed the last trade at $1.85 per share which meant it lost -$0.13 on the day or -6.57%% during that session. The IOVA stock price is -576.22% off its 52-week high price of $12.51 and 11.35% above the 52-week low of $1.64.
The consensus among analysts is that Iovance Biotherapeutics Inc (IOVA) is Buy stock at the moment, with a recommendation rating of 1.75. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 8 have rated it as a Hold, with 6 advising it as a Buy. 0 have rated the stock as Underweight.
Iovance Biotherapeutics Inc (NASDAQ:IOVA) trade information
Sporting -6.57%% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the IOVA stock price touched $1.85 or saw a rise of 16.67%. Year-to-date, Iovance Biotherapeutics Inc shares have moved -76.87%, while the 5-day performance has seen it change -17.41%. Over the past 30 days, the shares of Iovance Biotherapeutics Inc (NASDAQ:IOVA) have changed 5.41%.
Wall Street analysts have a consensus price target for the stock at $4, which means that the shares’ value could jump 53.75% from current levels. The projected low price target is $2.0 while the price target rests at a high of $6.0. In that case, then, we find that the current price level is -224.32% off the targeted high while a plunge would see the stock gain -8.11% from current levels.
Iovance Biotherapeutics Inc (IOVA) estimates and forecasts
The company’s shares have lost -76.31% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 4.17% over the past 5 years. Earnings growth for 2025 is a modest 12.10% while over the next 5 years, the company’s earnings are expected to increase by 44.97%.
IOVA Dividends
Iovance Biotherapeutics Inc is expected to release its next earnings report on 2025-May-08 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Iovance Biotherapeutics Inc (NASDAQ:IOVA)’s Major holders
Insiders own 0.48% of the company shares, while shares held by institutions stand at 81.25% with a share float percentage of 81.64%. Investors are also buoyed by the number of investors in a company, with Iovance Biotherapeutics Inc having a total of 398.0 institutions that hold shares in the company. The top two institutional holders are VANGUARD GROUP INC with over 25.95 million shares worth more than $208.12 million. As of 2024-06-30, VANGUARD GROUP INC held 9.1113% of shares outstanding.
The other major institutional holder is PERCEPTIVE ADVISORS LLC, with the holding of over 25.93 million shares as of 2024-06-30. The firm’s total holdings are worth over $207.98 million and represent 9.1052% of shares outstanding.
